Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varlilumab - Celldex Therapeutics

Drug Profile

Varlilumab - Celldex Therapeutics

Alternative Names: CDX-1127

Latest Information Update: 17 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; Oncothyreon; University of California at San Francisco; University of Virginia
  • Class Antigens; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD27 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours
  • Phase I/II Non-Hodgkin's lymphoma; Renal cell carcinoma
  • Phase I Glioma
  • No development reported Haematological malignancies; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 12 Dec 2018 Celldex completes a phase I/II trial in Solid tumours in USA (NCT02335918)
  • 13 Nov 2018 Celldex Therapeutics and University of Virginia initiates the phase I/II Mel-65 trial for Malignant melanoma (Combination therapy, Late-stage disease) in USA (NCT03617328)
  • 05 Oct 2018 Duke University plans the DERIVe phase II trial for Glioblastoma in USA (NCT03688178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top